The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks.
GlobalData on MSN2d
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticariaThe FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
Dupilumab in COPD was associated with decreased risk of mortality, emergency visits, exacerbations, and respiratory failure and infections.
Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations ...
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. This expansion positions Dupixent as the first targeted therapy for ...
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. This expansion positions Dupixent as the first targeted therapy for COPD, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback